Evidence map›Paper›PMID 40270200›Full record

ReviewHaematologica2025

Asparaginase-associated hyperammonemia.

Raheel Altaf Raja, Bodil Als-Nielsen, Allan M Lund, Hendrik Vilstrup, Kim Peder Dalhoff, Kjeld Schmiegelow

Abstract readReview
In one paragraph

Review in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raheel Altaf RajaDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen. raheel.altaf.raja@regionh.dk.
Bodil Als-NielsenDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen.
Allan M LundDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Medicine, University of Copenhagen.
Hendrik VilstrupDepartment of Hepatology and Gastroenterology, Aarhus University Hospital.
Kim Peder DalhoffDepartment of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Denmark; Clinical Pharmacology, Bispebjerg Frederiksberg Hospital, University of Copenhagen, Copenhagen Denmark.
Kjeld SchmiegelowDepartment of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Medicine, University of Copenhagen.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asparaginase is an essential drug in the treatment of acute lymphoblastic leukemia, and discontinuation of asparaginase therapy due to clinical toxicity or silent inactivation may lead to reduced event-free survival. Common toxicities include hypersensitivity reactions, acute pancreatitis, thrombosis, hepatotoxicity, and hyperlipidemia. In addition, several small case series have described asparaginase-associated hyperammonemia, the true frequency and clinical importance of which, both short- and long-term, remain unclear. Descriptions vary from asymptomatic patients to those with severe, acute encephalopathy leading to withdrawal of asparaginase therapy. The cause and management of the problem remain elusive. This review summarizes current knowledge on asparaginase-associated hyperammonemia, including its pathogenesis, clinical presentation, and possible interventions.

Indexed as

Antineoplastic AgentsAsparaginaseHyperammonemiaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansAntineoplastic AgentsAsparaginase

Identifiers

PMID40270200
PMCPMC12358781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.